Jump to content

All Activity

This stream auto-updates

  1. Yesterday
  2. “Alcohol manufacturers are the only tier of their own industry asking Congress to kill a category that Forbes has called a $38.5 billion industry.” By Jim Higdon, Cornbread Hemp In a new letter, alcohol manufacturers are again begging lawmakers to ban THC products made from hemp. On November 12, six trade associations led by the Beer Institute and the Distilled Spirits Council of the United States wrote to every member of Congress to declare their “unequivocal support” for the federal ban on hemp products containing more than 0.4 milligrams of THC per container. Their central argument is “the myriad of concerns that have been raised by state attorneys general, law enforcement organizations and public health advocates.” It’s nothing we haven’t seen before from alcohol manufacturers. But this time, by citing state attorneys general, they are presenting evidence that they helped create. According to Politico’s recent reporting, lobbyists for Anheuser-Busch, Molson Coors and Diageo urged state attorneys general to support letters opposing any congressional delay of the hemp ban. In one email, a lobbyist for Anheuser-Busch reportedly asked North Dakota’s attorney general for help against “fringe U.S. Senators who would like to extend the [hemp] loophole by another year.” Shortly thereafter, the North Dakota attorney general joined 34 others who asked Congress to reject any effort to delay the ban. Now those companies’ trade groups cite the concerns of the attorneys general as if they arose on their own. Once this feedback loop is visible, the rest of the letter falls apart. It calls hemp’s regulatory proposals “last-minute” and “slapdash.” And yet the only thing slapdash here is the manufacturers’ muddled opposition to commonsense regulation. A year ago, five of these groups asked Congress to pull hemp THC products until a federal framework existed and said they “stand ready to work with Congress and the Administration” to write one. Now they have moved the goalposts, objecting that the frameworks before Congress have had no hearing or markup. Yet the ban they are defending hardly followed regular order. The full Senate voted to strip the hemp ban out of an appropriations bill in August 2025, but the ban came back three months later, shoved into the deal that ended the longest government shutdown in American history. In their new letter, the manufacturers call hemp “largely unregulated, untested and untaxed.” That’s not true, either. Minnesota taxes hemp edibles and beverages at 15 percent of gross receipts, plus sales tax. Kentucky’s alcohol regulators oversee hemp beverages, cap them at 5 milligrams of THC per serving and tax them at $1.92 a gallon, 24 times the state’s per-gallon excise tax on beer. The trade groups boast that alcohol is governed by more than 4,000 federal laws and regulations, and that they know “the significant time, effort and expertise required” to build such a system. Hemp businesses are asking to join that system. Two bipartisan bills would regulate hemp beverages like alcohol: the Lawful Hemp Protection Act, from Reps. Andy Barr (R-KY) and Angie Craig (D-MN), and the Beverage Regulatory Parity Act, from Reps. Beth Van Duyne (R-TX) and Greg Landsman (D-OH). The other two tiers of the alcohol business support those bills. Wine & Spirits Wholesalers of America, whose members distribute over 80 percent of the wine and spirits sold at wholesale, has endorsed both. Retailers including Total Wine & More formed the Beverage Alcohol Merchants Coalition to press for regulation. Alcohol manufacturers are the only tier of their own industry asking Congress to kill a category that Forbes has called a $38.5 billion industry. In this new letter, the trade groups also mention “non-intoxicating cannabidiol (CBD)” as if they support it, while demanding a law that would outlaw full-spectrum CBD products, which carry trace amounts of THC. In April, President Donald Trump asked Congress to keep full-spectrum CBD legal, and Medicare now covers it in a pilot program for products with up to 3 milligrams of THC per serving. Giving lip service to CBD while working to outlaw the CBD products the president asked Congress to protect is a dangerous game. Lobbyists for these alcohol manufacturers prodded attorneys general to warn Congress about a competitor so the hit job wouldn’t have their fingerprints on it, but Politico’s reporting has pulled back the curtain. Congress should see this for what it is: protectionism at its most cynical. Jim Higdon is a co-founder and the chief communications officer of Cornbread Hemp, based in Louisville, Ky. Read the alcohol industry’s hemp letter below: The post Alcohol Manufacturers Pushing Congress To Ban Hemp Products Live In Their Own Anti-THC Echo Chamber (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  3. The U.S. Postal Service (USPS) is pushing back against a new program from Georgia companies that plan to use certified mail to deliver marijuana to patients in the state’s medical cannabis program—but it says it is actively considering a policy change in light of the Trump administration’s move to federally reschedule the drug. “Medical marijuana in all forms is currently nonmailable under any circumstances,” Felicia Lott, senior public relations representative for USPS, told Marijuana Moment, “but the Postal Service and the United States Postal Inspection Service are currently reviewing the mailability of medical marijuana in light of the recent reclassification” by the Drug Enforcement Administration (DEA). “The DEA’s reclassification of medical marijuana was limited to marijuana products approved by the U.S. Food and Drug Administration and products subject to a state medical license as a Schedule III substance,” she said. “In the event medical marijuana is deemed to be mailable in the future, it will be treated the same as other prescription drugs containing controlled substances for mailing purposes.” It’s not clear why USPS is conducting a review about a potential policy change instead of automatically allowing state-licensed medical cannabis to be shipped in the mail given that it became a federally legal Schedule III substance under an order issued by Attorney General Todd Blanche in April. Lott did not immediately respond to Marijuana Moment’s follow-up questions about how soon USPS may arrive at a decision on mailability of Schedule III state-licensed medical cannabis, or where and how the ultimate decision would be announced to the public and stakeholders. On Tuesday, Botanical Sciences, a Georgia-licensed medical marijuana provider, and Edibles.com, a sister company of Edible Arrangements, announced that they are partnering on what they said is the “nation’s first medical cannabis shipping program”—with a spokesperson telling Marijuana Moment that they planned to use USPS certified mail for the shipments. The effort comes weeks after the Georgia Access to Medical Cannabis Commission (GMCC) approved regulations that allow medical cannabis deliveries in the state, with officials specifically saying that USPS and private carriers like FedEx, UPS and DHL could participate. Andrew Turnage, executive director of GMCC told Marijuana Moment on Wednesday that he is “pleased to see” USPS “finally doing what states did seven months ago, which is to read the DEA rescheduling order.” “States are decades ahead of federal agencies with marijuana regulation and stand ready as a qualified and experienced resource to help the feds get it right,” he said. “Hopefully USPS will ‘get it right’ without the Government Accountability Office having to weigh in on what’s right there in black and white.” Meanwhile, a pair of Republican U.S. Senators sent a letter last month urging USPS not to participate in medical marijuana deliveries in Georgia or other states. “It is our understanding that marijuana cannot currently be mailed at all using the USPS,” Sens. James Lankford (R-OK) and Ted Budd (R-NC) said in a letter to Postmaster General David Steiner. “However, some states are under a different impression.” “While Georgia does not have the authority to alter current USPS regulations, we are concerned that USPS will alter its regulations to allow for these shipments,” the GOP senators wrote in the letter. “We strongly oppose any effort to allow the shipment of marijuana.” Another USPS official, when contacted by Marijuana Moment in August, declined to clearly state the agency’s position on participating in medical marijuana deliveries. Nikolaj Hagen, a senior public relations representative for USPS, pointed to general regulations on the mailability of controlled substances. USPS’s Lott, in her email to Marijuana Moment this week, also cited the same rule, saying it “provides the regulatory framework for the mailability of hazardous or restricted materials, including prescription drugs containing controlled substances.” The regulations state that if distribution of a controlled substance is unlawful, “then the mailing of the substance is also unlawful.” Mailing of controlled substances in domestic mail, they say, is only acceptable under three conditions—perhaps the most applicable of which allows shipping of prescription medications “when mailed by drug manufacturers or their registered agents, pharmacies, medical practitioners, or other authorized dispensers, as permitted by 21 CFR § 1307.11, or in compliance with any regulation of the FDA or other applicable law.” While state medical marijuana laws have allowed patients to access it via doctors’ recommendations, and not the formal prescription process due to federal prohibition, the cannabis rescheduling order that Attorney General Todd Blanche issued in April contains a provision that seems to deem those recommendations as prescriptions for the purposes of federal law. Meanwhile, as USPS weighs a potential policy change on the mailability of medical marijuana, other federal agencies are also taking steps in response to the Trump administration’s rescheduling move. In April, the U.S. Department of the Treasury and Internal Revenue Service (IRS) said they plan to issue new tax guidance for the marijuana industry following the rescheduling announcement. Rescheduling will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions they’re currently barred from under an IRS code known as 280E that doesn’t apply to Schedule III substances. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) also recently posted a draft update to gun purchase form to acknowledge the federally legal status of medical marijuana under rescheduling. The Drug Enforcement Administration (DEA) has launched a process to federally register state-licensed medical cannabis businesses. The Department of Transportation, on the other hand, issued guidance saying that use of state-legal medical cannabis is still no excuse for a positive drug test by truck drivers, pilots and other safety-sensitive workers. The Department of War issued a memo making clear that marijuana use by military service members and civilian employees of the department remains prohibited, even under federal cannabis rescheduling. The post USPS Says Medical Marijuana Isn’t Mailable ‘Under Any Circumstances,’ But Weighs Possible Policy Change Under Rescheduling appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  4. NC gov’s marijuana council; Federal hemp debate heats up with new bill; Congressional psychedelics hearing; TX legalization revenue Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Hold on, just one second before you read today’s news. Have you thought about giving some financial support to Marijuana Moment? If so, today would be a great day to contribute. We’re planning our reporting for the coming months and it would really help to know what kind of support we can count on. Check us out on Patreon and sign up to give $25/month today: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Sens. Tim Sheehy (R-MT) and Amy Klobuchar (D-MN) filed a bill to prevent the federal recriminalization of hemp THC products that’s scheduled for next month and replace it with a system of regulations as an alternative to prohibition. Rep. James Comer (R-KY) said the best shot for keeping hemp THC products federally legal is by attaching provisions to a must-pass spending bill—saying that their currently planned recriminalization on December 11 “makes me so mad because the industry is working, and it’s a huge success story.” Georgia companies are launching a new medical cannabis delivery service under newly enacted state rules using U.S. Postal Service certified mail—even as the federal agency refuses to clarify its stance on marijuana’s mailability in light of rescheduling and as U.S. senators press it not to participate. The House Veterans’ Affairs Subcommittee on Health will hold a hearing on Wednesday focused on increasing military veterans’ access to psychedelic treatments—with officials from the U.S. Department of Veterans Affairs set to testify alongside medical professionals and researchers. The North Carolina Advisory Council on Cannabis that was appointed by Gov. Josh Stein (D) met to discuss draft recommendations for a final report that is due next month—including state control of marijuana dispensaries and other issues such as taxes, expungements, potency and packaging rules. A Texas senator said he wants to use revenue from marijuana legalization to fund Gov.-elect Gina Hinojosa’s (D) plan to send $1,500 economic relief checks to every household in the state. Veterans of Foreign Wars and other military veterans groups sent a letter urging congressional leaders to keep hemp THC products federally legal by calling off a ban scheduled for next month and replacing it with regulations for the industry. Dasheeda Dawson, a former New York City and Portland cannabis regulator, argues in a new Marijuana Moment op-ed that the blue wave in this month’s elections “can open doors” to reform but that sustainable and equitable change “requires the courage to build something better on the other side.” “Some of the states that have struggled most to translate cannabis equity into meaningful outcomes have been led by Democrats. Some of my most difficult conversations about what equity actually means happened in jurisdictions where political leaders embraced it the loudest… Somewhere between designing markets, allocating licenses and determining who gets to participate, the fight for freedom became consumed by the business of legalization. Meanwhile, criminalization persists, stereotypes remain embedded in public policy and access to the plant is still treated as a privilege to be negotiated.” / FEDERAL The Department of Justice’s Office of the Pardon Attorney submitted a routine request for permission from the White House Office of Management and Budget to continue collecting public information via the application for certificates of pardons for federal marijuana offenses that was initiated by President Joe Biden, estimating that a “potential pool of approximately 350 applicants may apply.” Sen. Chuck Grassley (R-IA) and six other senators sent a letter urging the Drug Enforcement Administration and Food and Drug Administration to explain and reconsider changes to an emergency scheduling order for kratom-related substances. / STATES California’s attorney general touted enforcement efforts against illegal cannabis operations. Attorneys for Virginia’s Senate president pro tempore, who is facing federal marijuana and corruption charges, are asking a judge to sanction Attorney General Todd Blanche and Federal Bureau of Investigation Director Kash Patel over comments they made at a press conference about her indictment. New Hampshire senators discussed the prospects for legalizing marijuana in the 2027 session. Massachusetts regulators approved rules allowing drive-thru windows at marijuana retailers. Vermont regulators began accepting applications for cannabis event permits. Michigan regulators filed complaints against marijuana businesses over alleged violations. Mississippi regulators published a frequently asked questions document about medical cannabis. Oregon regulators will consider changes to rules on the hemp registry application process on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Nigerian African Action Congress presidential candidate Omoyele Sowore is calling for cannabis legalization. / SCIENCE & HEALTH A study found that “cannabidiol-rich hemp cultivars suppress cannabis aphid populations and alter detoxification gene expression.” A study of rats concluded that “chronic intermittent administration of a ∆9-THCA-enriched extract reconfigures the aged phenotype, prioritizing metabolic maintenance and neuroprotection,” suggesting that full-spectrum cannabinoids serve as a viable geroprotective for neuroinflammatory stress.” / ADVOCACY, OPINION & ANALYSIS A poll of current and retired Massachusetts law enforcement officers found that 92 percent want to keep licensed marijuana sales legal. The Canadian Association of Social Workers is asking lawmakers to decriminalize drugs. / BUSINESS Glass House Brands Inc. reported quarterly revenue of $56.8 million and a net loss of $10.1 million. POSaBIT Systems Corporation reported quarterly revenue of $2.3 million and a loss of $0.1 million. / CULTURE Podcaster Joe Rogan again suggested that opposition to cannabis reform was partly to blame for Republicans’ losses in the midterm elections. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post New medical cannabis delivery plan involves USPS (Newsletter: November 18, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  5. dario.neeko

    The Truth About Women in Cannabis

    I've lately began the weblog, the data a person supply on this website offers assisted me personally significantly. Many thanks with regard to all your period & function. mpo888 link
  6. Enjoying your downtime reaches a whole new level when you utilize a trusted Independent bijwasan Escorts Service for your social and personal needs. The remarkable attention to detail and friendly nature of the companions guarantee a wonderfully stress-free, delightful, and memorable evening from start to finish.
  7. hannana

    Eyes Wide Love: Tokeativity Back to the 90’s

    Word association games connect words through shared meanings, daily games experiences, or familiar concepts.
  8. Yatesda

    Apply to Tokeativity® Canna Mama Con

    This sounds like such a fantastic initiative! Connecting canna mamas and sharing wisdom is so important. I love the idea of creating a supportive online space. It makes me think about how we often crave community, even when dealing with big, impactful topics. This conference could really be a Solar Smash for those looking for genuine connection and knowledge!
  9. Sienna Crook

    What Do Abortion and Cannabis Have in Common?

    Navigating this tightrope requires empathy and open minds. I remember a workplace ethics committee grappling with a similar conundrum, where individual beliefs clashed with company policy, almost like a real-life Connections Game.
  10. Last week
  11. A bipartisan duo of U.S. senators have filed a new bill that would prevent the federal recriminalization of hemp THC products that is currently scheduled to go into effect next month while instituting a set of new regulations as an alternative to prohibition. Sens. Tim Sheehy (R-MT) and Amy Klobuchar (D-MN) introduced the Hemp Guardrails Act on Tuesday. The legislation would raise the legal threshold for hemp to one percent total THC on a dry-weight basis—with an exception to go above that for in-process materials—and create a new category of prohibited cannabinoids that include delta-8 THC, delta-10 THC and THC-O-acetate , while also restricting the manufacturing or synthesizing of those compounds outside of the hemp plant. The legislation would continue allowing conversions for CBD, delta-9 THC and other natural hemp compounds outside of the plant, but only if it results in a naturally occurring end product. Raw floral hemp material, smokable hemp flower or hemp pre-rolls would be barred from entering interstate commerce. There would be an age limit of 21 to possess and consume hemp cannabinoid products, and they would need to be grown, processed and packaged within the U.S. to be legal. The bill also seeks to establish categories for hemp-derived products and supplements under the Federal Food, Drug, and Cosmetic Act and directs the Food and Drug Administration (FDA) to set rules for packaging, labeling, manufacturing, testing, registration and recalls within 180 days. Certain industrial hemp products not containing cannabinoids—such as seed, seed oil, and hempseed protein—would be considered food additives, subject to applicable safety requirements. The legislation preserves the authority of states to enact stricter hemp regulations but prohibits them from blocking the interstate transportation of compliant products. “We’re taking a commonsense approach to this issue,” Sheehy said in a press release. “Our bill will put every bad actor in the hemp space out of business and keep intoxicating products out of the hands of children. It will also stop Congress from turning the farmers, veterans, and cancer patients who rely on these products into criminals overnight.” Klobuchar, who was recently elected governor of Minnesota and will be leaving the Senate soon, said her state is “is a national leader in hemp” and “has shown that we can protect kids and support responsible hemp businesses.” “But a looming federal ban on hemp products is threatening farmers, brewers, small businesses, and consumers across Minnesota and the country,” she said. “This new bill with Senator Sheehy would keep safe hemp products on store shelves, protect consumers from dangerous products, and ensure that farmers and small businesses can continue to operate, grow, and create jobs.” Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, the president signed new legislation containing provisions that redefined hemp to make it so only products with 0.4 milligrams of total THC per container would remain legal after November 12. Under provisions included in a separate funding bill Trump signed this September, however, the effective date of the ban for most products was pushed back to December 11 to give lawmakers more time to craft regulations for hemp derivatives. There was a carve-out, however, to allow the recriminalization on November 12 of synthetic cannabinoids “that are not capable of being naturally produced by a Cannabis sativa L. plant.” Jonathan Miller, general counsel for the U.S. Hemp Roundtable, said that “all responsible players in the hemp industry are united in support of the bipartisan Hemp Guardrails Act of 2026.” “The bill would not only preserve the vibrant hemp industry threatened by an ill-advised ban, it would also serve to protect children and vulnerable consumers by cracking down on bad actors,” he said. “The bill says: No to sales to minors. No to imports from China. Yes to good manufacturing practices and third-party testing. No to copycat products that appeal to kids. No to ‘gas station weed.’ Yes to non-intoxicating CBD and low-dose hemp beverages.” Meanwhile, a top GOP congressman is pushing to attach provisions to keep hemp products legal to larger spending legislation in the coming weeks. “The best opportunity, in my opinion, is to get this on a bill that is going to pass,” Rep. James Comer (R-KY), who chairs the House Oversight and Government Reform Committee, said. “The only bill that I think that absolutely, positively has to pass is going to be another continuing resolution, which is what got us here to begin with.” Rep. Morgan Griffith (R-VA) similarly recently floated the idea of including hemp extension and regulation language in a broader budget reconciliation bill. Miller of U.S. Hemp Roundtable said he group is looking forward to working with Sheehy and Klobuchar to secure their bill’s provisions “inclusion in the next spending bill or continuing resolution that will keep the government open for business.” The Congressional Research Service noted in a recent report that the Food and Drug Administration (FDA) is now more than nine months late in fulfilling a legal mandate to publish a list of known cannabinoids and guidance on hemp product containers that was included in last year’s hemp product recriminalization legislation. Aside from the new Senate legislation, a number of lawmakers from both chambers and both parties have filed or are circulating a growing number of bills to prevent the scheduled federal recriminalization of hemp THC drinks and other products. Comer, for example, is circulating legislation that would delay a planned federal ban on hemp THC products and institute some regulations—including packaging requirements, testing rules and age limits. Reps. Beth Van Duyne (R-TX) and Greg Landsman (D-OH) introduced a bill to keep hemp THC drinks legal while taxing and regulating them like alcohol. Separately, Rep. Andy Barr (R-KY), filed a lengthier proposal to prevent the federal recriminalization of hemp THC products and put in place a number of regulations for manufacturing, labeling, sales and taxation of hemp-derived products, including an age limit of 21. Griffith and Rep. Marc Veasey (D-TX) introduced a measure to allow continued sales of hemp THC products to adults over 21, with new regulations, Several Republican lawmakers recently spoke to Marijuana Moment about the kinds of rules they would like to see enacted to keep hemp THC products legal. This week, Veterans of Foreign Wars and other military veterans groups sent a letter urging Congress to keep hemp THC products legal. The post Bipartisan Senators File Bill To Keep Hemp THC Products Federally Legal As Next Month’s Scheduled Ban Looms appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  12. A North Carolina governor-appointed cannabis commission is reviewing draft recommendations as it prepares to issue its final report next month on how the state should legally regulate THC—including state control of marijuana dispensaries. Members of the North Carolina Advisory Council on Cannabis have been meeting regularly since Gov. Josh Stein (D) formed the body last year, including in subcommittees focused on market structure, taxation and public safety—and the full panel came together on Tuesday to discuss a set of recommendations that will inform a final report that is due by the end of the year. Among other issues, the panel appears to be settling on recommending that lawmakers create a regulated adult-use marijuana program allowing possession by and sales to adults over 21 years of age that would include specific protections for patients without creating a separate and distinct medical cannabis program. One of the more notable draft recommendations surrounds the structure of the legal market. While private businesses would be licensed to cultivate and process marijuana products, the state would play a more active role in controlling cannabis retail outlets similar to how it handles liquor, beer and wine through the Alcoholic Beverage Control Commission (ABC). Lawrence H. Greenblatt, the state health director and chief medical officer at the North Carolina Department of Health and Human Services, said at the meeting that the state would “rather tightly” oversee sales to consumers, which would “allow for retail outlets that essentially are not promoting more use of cannabis products.” “It’d be essentially kind of clean, no posters, no advertising,” he said, noting it would be similar to the cannabis sales model in Quebec, Canada. “The state would contract that out to a vendor or vendors, and wouldn’t actually own the product,” Greenblatt said, suggesting that the model wouldn’t run afoul of federal laws. Rather than create separate systems for recreational marijuana, medical cannabis and hemp products, the council is focused on regulating the intoxicating molecule of THC through the creation of a new regulatory body to oversee the overall industry. The draft recommendations discussed at Tuesday’s meeting include provisions concerning advertising restrictions, rules for packaging and labeling, standards for product potency and testing, expungements for prior convictions, banning public smoking and vaping, youth prevention efforts, law enforcement resources and impaired driving prevention. When it comes to taxation, the panel appears to be preparing to recommend that lawmakers choose between taxing marijuana by price, as most other states have done, or applying a tax by based on products’ THC potency. Greenblatt said that the council has undertaken a “tremendous lift” in recent months. “This is really hard, complicated material. We’ve asked a lot of you, a lot of reading, meetings, listening to speakers, thinking—some great conversation and insights,” he said. “And this is a really important issue for the state—important for public health and public safety.” “As we all know, North Carolina is facing a public safety and public health problem,” Greenblatt said. “Cannabis with intoxicating levels of THC is widely available and unregulated. Concurrent lack of regulation, including no minimum age for sale, no labeling requirements or testing standards, poses a threat to all North Carolinians, particularly our youth.” Members of the council did not vote on the recommendations at Tuesday’s meeting but will do so in the coming weeks ahead of the final report being issued. The council’s consideration of the draft recommendations comes shortly after Democrats took control of the state House of Representatives in this month’s midterm elections and narrowed Republicans’ majority in the Senate to just one seat—which advocates believe better positions the state to move ahead with marijuana reform than ever before. House Speaker-elect Robert Reives (D) said following the election that “decriminalization of marijuana has been on top of everybody’s minds.” The incoming top House official also spoke about the benefits of medical cannabis, particularly for military veterans. “I’ve got a veteran family,” he said. “My dad served. My uncle served, and all that. And it’s just, I want everything we can to help our veterans, and that is one of the top items that people have talked about.” The North Carolina Senate under GOP control has already approved legislation to legalize medical cannabis several times during recent sessions, though House Republican leadership has refused to allow the reform to advance. Stein, meanwhile, supports broader marijuana legalization and convened the state council last year to evaluate options for updating cannabis laws. The governor-appointed cannabis commission in North Carolina issued an interim report in April initially recommending that the state move away from a criminalization-based approach to the plant and toward a system of “robust” regulations that provide for adults’ legal access to THC products. The North Carolina Advisory Council on Cannabis said in the initial report that that the current “absence of regulation for North Carolina’s intoxicating cannabis market raises numerous concerns,” noting that hemp products are readily available yet largely unregulated and that marijuana remains prohibited altogether in the state, even for medical use. “Compared to regulated marijuana frameworks in other states, this environment presents identifiable risks,” the interim report says. “While some operators voluntarily implement consumer protection protocols, these safeguards are not required under state law.” Stein, for his part, thanked the group for its “expertise, hard work, and thoughtful deliberation” put into the initial report and reiterated his support for legalizing marijuana. Members are tasked with developing and submitting initial recommendations on a “comprehensive cannabis policy, including any proposed legislation,” with a final report due by December 31. Meanwhile, the governor has continually pressured the GOP-controlled legislature to advance marijuana reform. In August, Stein called on lawmakers to broadly legalize and regulate cannabis in a way that “protects kids” while they were considering a narrower bill to restrict hemp THC and kratom products. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In September, a poll showed that North Carolinians strongly support legalizing medical marijuana, and that a majority wants to go even further by legalizing cannabis for recreational use. During his time as the state’s attorney general, Stein led a separate task force under then-Gov. Roy Cooper (D) that examined racial injustice issues and ultimately recommended decriminalizing marijuana and studying broader legalization in response to racially disparate enforcement trends. A tribe in North Carolina, the Eastern Band of Cherokee Indians, launched the state’s first marijuana dispensary in 2024—despite the protests of certain Republican congressional lawmakers. Democratic lawmakers recently filed legislation to allow voters to decide whether to legalize marijuana for personal or medical use at the ballot box this November, though that did not advance. Meanwhile, bipartisan North Carolina lawmakers have been stepping up the push for psychedelics reform legislation. The post North Carolina Governor’s Cannabis Council Weighs Recommendations For Legally Regulating THC, Including State-Controlled Dispensaries appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  13. “Some of the states that have struggled most to translate cannabis equity into meaningful outcomes have been led by Democrats.” By Dasheeda Dawson, The WeedHead™ The Democrats won big. Cannabis legalization could be next. But will cannabis equity and freedom actually win? That’s the question we should be asking after the 2026 midterms, as shifting political dynamics renew optimism about cannabis reform in states like Texas, Pennsylvania, North Carolina and Georgia. Texas lawmakers have introduced legalization legislation. North Carolina’s legislative leadership has floated decriminalization. Across the country, new political possibilities are reopening conversations about cannabis policy. For advocates who have spent decades fighting prohibition, these developments offer renewed opportunity. Before we celebrate the next wave of legalization, we should reckon with what the last one taught us. Some of the states that have struggled most to translate cannabis equity into meaningful outcomes have been led by Democrats. Some of my most difficult conversations about what equity actually means happened in jurisdictions where political leaders embraced it the loudest. Cannabis transcends party lines. Education and access is a human rights issue, and getting it right is everyone’s responsibility. I’ve spent a decade in this work, five of those years inside government. I managed Portland, Oregon’s cannabis program and served as the founding executive director of Cannabis NYC. Along the way, I’ve been an advocate, educator, entrepreneur and patient. From every one of those seats, I’ve witnessed the distance between legislative promises and lived experience. The next chapter of cannabis reform needs a new blueprint. The Equity Paradox Equity programs were built to repair the harms of prohibition. For too many licensees, they’ve become the newest harm. In conversations with equity licensees across the country, more than half have told me some version of the same thing: if they knew then what they know now, they wouldn’t have pursued a license. These are field observations, gathered one licensee at a time, and the sentiment is consistent enough to demand attention. New York offers a troubling example. Its Conditional Adult-Use Retail Dispensary (CAURD) program created a historic opportunity for justice-involved entrepreneurs. Some have built successful businesses, created jobs and opened doors that prohibition kept closed for generations. Many others have spent years navigating delays, debt, real estate challenges and costly compliance requirements. The Dormitory Authority of the State of New York (DASNY) -backed Social Equity Cannabis Investment Fund became a case study in how assistance meant to accelerate opportunity can become another way to incarcerate people through financial burdens. Imagine surviving criminalization, qualifying for an equity license and then discovering that participating legally could threaten your health and financial future. We built pathways to ownership without building the conditions for ownership to succeed. That’s the equity paradox. The next state to legalize should confront it before repeating it. Good Legislation Is Only The Beginning Equity looks great on paper. Implementation is where it lives or dies. I learned that firsthand in Portland. The city’s cannabis equity and community reinvestment commitments existed before I arrived. Building the systems to deliver on those commitments required intentional leadership, community engagement and operational discipline. Across the country, cannabis tax revenue has been celebrated as a tool for repairing communities disproportionately harmed by prohibition. The gap between allocating those dollars and delivering measurable benefits can be enormous. A budget allocation is a promise. A measurable improvement in people’s lives is an outcome. We’ve spent far too much time applauding promises. Licensing works the same way. The number of equity licenses issued tells us little about whether those businesses are profitable, whether their owners are building wealth or whether their communities are better off. A license count is a headline. A profitable equity business is proof. Economic participation, particularly dispensary ownership, has dominated the definition of cannabis equity. The CHEM Pillars of Health Equity measure it across four interconnected dimensions: social equity in the structures and relationships that sustain collective well-being; economic equity in fair access to resources and sustainable livelihoods; environmental equity in the places where communities live, work, and grow; and human equity in dignity, ancestral knowledge, and the right to make informed decisions about one’s own health. Dispensary ownership speaks to one pillar. Cannabis reform has to answer for all four. A community can generate millions in cannabis sales while its residents remain criminalized, patients struggle with affordability and promised reinvestment never arrives. A thriving cannabis market and a healthy community are two different achievements. That should change how we define success. We Legalized The Market And Kept The Stigma While working in government, I discovered that some of the people shaping cannabis policy understood the least about the plant. It was one of the most frustrating parts of the job. Even in New York City, where I spent considerable time educating colleagues across agencies, including public health and mental health officials, deeply rooted stereotypes continued to shape conversations about cannabis. Science has evolved. Public opinion has shifted. Laws were changing. Institutional understanding lagged behind all three. That knowledge gap has consequences. We still impose arbitrary possession limits, restrictive home cultivation rules and expensive compliance requirements while treating cannabis activity outside licensed commerce as inherently suspect. We cannot regulate our way out of ignorance. Texas offers a particularly revealing example. An expansive hemp-derived cannabinoid market emerged under the 2018 Farm Bill, including products marketed as “THCA flower.” THCA is naturally abundant in marijuana flower until heat converts it to THC so the distinction was an absurd loophole. That market rapidly grew with limited oversight, only to face sweeping restrictions and renewed criminal penalties. Now, with a federal hemp ban looming, Texas lawmakers are introducing proposals to legalize adult-use cannabis. Texas has turned the same plant into a commodity, then a crime and now a campaign promise. What have lawmakers learned from this experience? Judging by the latest proposals, not nearly enough. Newly introduced Texas legislation proposes a two-ounce possession limit and permits twelve plants for home cultivation. Sounds great, except the possession threshold preserves an arbitrary line between lawful conduct and criminal exposure. Twelve plants per person should be the minimum for meaningful home cultivation rights, with additional allowances reflecting patient needs, caregiving, genetic preservation and personal autonomy. Full decriminalization should be the foundation of reform. Public safety standards should address actual harms, and an arbitrary quantity threshold should never be the line between a law abiding citizen and a criminal. Protect the people. Expand their ability to understand and benefit from the plant. That’s the job. Federal Reform Is Exposing The Contradictions The federal government is finally running into the contradictions state regulators have lived with for years. The Schedule III framework recognizes cannabis’s accepted medical use while drawing a federal distinction between qualifying medical activities and state-licensed adult-use operations. Regulators know how artificial that separation is. The same cannabis product can be sold through either market, often to consumers seeking the same benefits. Sleep, pain and anxiety consistently rank among the leading reasons people shop in adult-use cannabis markets. Focus is another common motivation. Cannabis remains medicinal no matter which dispensary counter it crosses. Federal policy is still constructing separate categories of legitimacy around the same plant, risking an unprecedented regulatory divide within a single controlled substance. For years, “regulate cannabis like alcohol” was the rallying cry of legalization campaigns. It made a great slogan. Cannabis consumer behavior tells a more complicated story. An over-the-counter health and wellness model offers a more relevant starting point for many cannabis products, borrowing elements of alcohol regulation where warranted. A whole-plant approach could go further, establishing a unified regulatory foundation for cannabis that recognizes its medicinal, agricultural, industrial and adult-use applications. Product standards could reflect actual composition, effects and risks, while licensing and compliance requirements accommodate different activities within one coherent legal framework. That approach allows states to meet federal medical requirements where necessary while keeping one market for one plant. Our laws should follow the science of the plant. Its classification has followed politics long enough. Instead, policymakers remain consumed with developing markets, establishing regulatory categories, and choosing economic winners and losers. Meanwhile, sixteen governors have once again urged Congress to pass the SAFE Banking Act. We’ve been here before. As chair of the Cannabis Regulators of Color Coalition, I helped challenge the assumptions behind this legislation years ago. SAFE protects financial institutions that serve cannabis businesses. It guarantees nothing about equitable lending or meaningful access to capital for the entrepreneurs who need it most. The familiar story goes like this: cannabis businesses run on cash, and banking reform will solve the crime that cash attracts. Regulators on the ground have seen a far more complicated reality. Access to affordable capital is the bigger, harder problem which remains unresolved with the proposed legislation. And the same bill, carrying the same promises, still dominates federal reform conversations. We’ve spent years trying to free the money while leaving the plant and the people federally criminalized. At the same time, federal restrictions on hemp-derived cannabinoids threaten another segment of the cannabis economy, deepening the contradictions between federal policy and state legalization. The plant hasn’t changed. Our rules keep changing around it. Rescheduling may benefit qualifying medical operators. Full descheduling, decriminalization, whole-plant access and the federal treatment of adult-use businesses remain unresolved. Those questions deserve to lead the next chapter of reform. The Next Wave Needs A New Blueprint Every generation of legalization has fixed some of the last one’s mistakes and made new ones of its own. Early adult-use states largely left equity out of their statewide frameworks, while cities like Oakland, Los Angeles and Portland pioneered local efforts to address the harms of prohibition. Massachusetts became the first state to establish a statewide cannabis social equity effort, followed by Illinois, New York, New Jersey, Maryland and others that built equity into their legalization frameworks. Each generation has expanded the conversation, created opportunities, and exposed challenges for the next. That’s progress. Progress also demands accountability. We have to be willing to critically grade our own work. Through that lens, we must acknowledge where we’ve lost the plot. Somewhere between designing markets, allocating licenses and determining who gets to participate, the fight for freedom became consumed by the business of legalization. Meanwhile, criminalization persists, stereotypes remain embedded in public policy and access to the plant is still treated as a privilege to be negotiated. We’ve become experts at designing cannabis markets while still struggling to define cannabis freedom. The next wave also demands a shift in advocacy. For too long, the pursuit of whatever legislation can pass has shaped the boundaries of what we’re willing to fight for. Political feasibility has become a substitute for policy vision. Our responsibility as advocates is to establish the foundations of freedom and hold legislation accountable to them. Full decriminalization, meaningful cultivation rights, science-based education, health autonomy and equitable access must anchor the framework from day one. Texas, Pennsylvania, North Carolina, Georgia and other states entering a new political chapter have the benefit of our collective experience. They can build on what worked, confront what failed, and write policies that start with the rights we intend to protect. The markets can follow. The real measure of cannabis equity must be rooted in measurable outcomes: freedom from criminalization and collateral consequences, more people educated and empowered to cultivate and access the plant, financially sustainable small businesses and community reinvestment that actually reaches the people it was intended to serve. Protecting our environment and preserving the plant’s cultural, medicinal, and agricultural value must be part of that equation. That’s how we measure progress. That’s how we measure equity. Political shifts can open doors. Sustainable reform requires the courage to build something better on the other side. The blue wave may set the stage for another chapter of legalization. After decades of prohibition and years of imperfect implementation, we owe ourselves more than another collection of licenses, tax revenue projections and recycled federal proposals. The next blueprint must measure how many people we’ve freed, how much knowledge we’ve shared, and how well we’ve protected the plant for generations to come. Free the plant. Free the people. Dasheeda Dawson is a cannabis policy strategist, educator, entrepreneur and former government regulator in New York City and Portland, Oregon. She is the founder of The WeedHead™ & Company and the bestselling author of How to Succeed in the Cannabis Industry: The Blueprint They Never Gave Us, 4th Edition. The post The Election’s Blue Wave Won’t Save Cannabis Equity, But A New Blueprint Might (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  14. A congressional committee is scheduled to hold a hearing about increasing military veterans’ access to psychedelic treatments this week—with officials from the U.S. Department of Veterans Affairs (VA) set to testify alongside medical professionals and researchers. The hearing—titled “Psychedelic-Assisted Therapies for Veterans: The Path Forward”—will be held before the House Veterans’ Affairs Subcommittee on Health on Wednesday. Andrew Gradison, a senior advisor to the under secretary for health at the VA’s Veterans Health Administration (VHA), said in written testimony posted by the panel that President Donald Trump’s administration “has taken decisive action to accelerate psychedelic research and eliminate regulatory obstacles that have historically slowed progress.” He cited an executive order Trump signed in April with the aim of expediting psychedelic therapy access, saying it was the “first EO in American history dedicated specifically to accelerating clinical research and regulatory review of psychedelics, underscoring the president’s firm commitment to advancing emerging treatments for serious mental illnesses.” Since then, “VA’s psychedelics research portfolio has grown substantially in response, and our interagency partnerships are driving rapid and safe scientific advancement,” Gradison said, noting that it is now conducting 21 active clinical studies on psychedelics to treat mental health conditions. He specifically cited a clinical trial VA announced in August to investigate whether psilocybin can help military veterans who are struggling with treatment-resistant depression. TOMORROW @ 2:15 PM ET: Health Chairwoman @RepMMM will lead an oversight hearing examining psychedelic-assisted therapy options and the path forward for veterans. pic.twitter.com/qPKf16M6RF — House Committee on Veterans' Affairs (@HouseVetAffairs) November 17, 2026 “VA strives to lead the Nation in exploring the therapeutic potential of psychedelic drugs,” Gradison said, adding that the department recognizes that substances such as psilocybin, MDMA and ibogaine “offer promising potential for the complex mental health conditions affecting many of the Veterans we treat.” The VA official also touted a memorandum of understanding his department signed with the Department of Health and Human Services (HHS) in July outlining a partnership to collaborate on research and development of psychedelic medicines to treat people struggling with serious mental health conditions. The agreement, he said “lays the groundwork for unprecedented VA-HHS operational cooperation on psychedelic trials.” “As we prepare for potential clinical implementation, VA remains anchored in three core priorities: first, ensuring Veteran safety above all else; second, building a rigorous body of evidence to determine which treatments work for which Veterans; and third, laying the foundation so that, pending all regulatory approvals, VA is positioned to be the first health care system in the Nation to deliver these treatments to Veterans. These priorities shape every research, clinical, and policy decision we make in this space.” Gradison said VA has already identified 10 facilities “with the expertise, physical space, and operational capacity needed to serve as early implementers, educators, or sites-in-training” with teams that are “experienced in psychedelic research protocols and are preparing to translate that experience into clinical care that maximizes Veterans’ safety if treatments are approved.” The VA official emphasized, however, that the department discourages self-medicating with psychedelics or using them to replace other mental health treatment options. Also testifying at Wednesday’s hearing will be Leith States, a former HHS acting assistant secretary for health who now runs the consulting firm States Strategies. He is calling on Congress to support psychedelic research that “answers the clinical questions veterans and clinicians face,” while requiring VA to set and track milestones for clinical readiness and access and holding the department accountable for patient safety and lasting improvement in veterans’ lives. “Doing our duty means investigating promising treatments with urgency and discipline, speaking plainly about what we know, and preparing the people and systems needed to deliver responsible, safe, and ethical care,” States’s testimony said. “Veterans’ needs should determine our priorities as we build on useful work across administrations, examine shortcomings honestly, and sustain the progress clinicians and researchers need to improve care.” The testimony of Marion Coe of Pinney Associates references her work to compile responses to a request for information (RFI) the bipartisan Congressional Psychedelics Advancing Therapies (PATH) Caucus issued seeking input from experts about how to best set up a regulatory framework for psychedelic medicines. Among other points, she emphasized that VA must “begin preparing its clinical infrastructure and workforce” before Food and Drug Administration (FDA) approval of any psychedelic treatments “if it is to be ready to expand access as rapidly and as safely possible.” “The central challenge is not simply whether these medicines can work,” Coe said. “It is whether we can build the infrastructure necessary to deliver them safely, ethically, and to the veterans who need them, and help as many patients who could benefit as safety and other considerations allow.” Mark Niciu, an assistant professor at the University of Iowa, used his testimony to explain his research addressing what he called the “major hurdle” of functional unblinding in psychedelic research, which is when participants and evaluators are able to tell which subjects are in the control or experimental group during a trial. “Expectancy bias is particularly salient in psychedelic medicine trials, where the drug’s effects are acute, intense, highly salient, and reinforced, for example, by the recent re-galvanization of classical psychedelics by the media, government, etc.,” he said. “When such drugs are compared with an inert or insufficiently matched placebo, participants and researchers immediately and accurately know their randomization assignment. In other words, there is ‘double’ functional unblinding, potentially affecting the thoughts and/or behaviors of both parties for the remainder of the trial.” Raquel Halfond, the senior director of evidence-based practice and health equity at the American Psychological Association, emphasized in her testimony the need for focus on transparency and accountability, infrastructure and associated therapy and workforce demands. “Each of these areas is necessary to make veteran protection and safety the utmost priority,” she said. The organization “encourages VA and all federal partners to adopt a stepped, interdisciplinary care model regarding the development of psychedelic-assisted therapy following rigorous and ethical research, with national minimum competencies; independent medical and psychological assessments; strong ethical safeguards and informed consent; on-site human monitoring; structured follow-up; and drug-specific staffing requirements,” Halfond said. “With strong VA research standards and clinical trial protocols being put in place, we are encouraged by the ability of the VA to lead the way with scientific rigor and integrity.” While not testifying in person at the hearing, Disabled American Veterans, Veterans of Foreign Wars, Special Forces Foundation and Mindbloom all submitted written statements for the record. Photo courtesy of Mark Groeneveld. The post Congress To Hold Hearing Focused On Psychedelic Therapy For Military Veterans This Week appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  15. Texas should legalize marijuana and use the revenue to fund the incoming governor’s plan to send a $1,500 economic relief payment to every household in the state, a Democratic senator says. “We can create new taxation as well that doesn’t affect families at home,” Sen. Roland Gutierrez (D) said in an interview with WFAA-TV. “Let’s look at cannabis.” The senator, who prefiled a bill last week to enact Gov.-elect Gina Hinojosa’s (D) proposal to send $1,500 checks to households across the state, criticized the state’s current laws—passed under a Republican legislature—that have allowed sales of hemp products in a way he said doesn’t provide for sufficient taxation. “Republicans legalized cannabis without ever taxing it in a real way,” Gutierrez said. “We can generate over $3 billion in taxing cannabis, clawing back the danger and the damage that they created over the last six years, and their amping up this hemp stuff across every convenience store in your community.” During the last legislative session, the legislature passed a bill to recriminalize hemp THC products that was ultimately vetoed by Gov. Greg Abbott (R). Following that veto, however, state agencies advanced restrictive rules that effectively banned many hemp products and which are currently being challenged in court. Meanwhile, Gutierrez’s bill for the $1,500 payments says that “extraordinary and sustained increases in the cost of housing, electricity, food, transportation, insurance, and other necessities have created a statewide household affordability emergency that threatens the ability of Texas households to obtain necessities and maintain stable housing.” The one-time checks to every household would be aimed at addressing what it calls the “immediate consequences of that calamity and protect the health, safety, and economic stability of residents of this state.” Texas Democrats won every statewide office on the ballot in this month’s midterm elections, as well as majority in the House of Representatives, but Republicans will maintain control of the Senate. Lt. Gov.-elect Vikki Goodwin (D), who will oversee the Senate in the role, said recently that legally regulating THC products will be one of her top priorities in the 2027 session. Democratic and Republican elected officials in Texas are discussing the possibility of teaming up across partisan lines to advance cannabis reform in the 2027 legislative session following this month’s election results that upended the GOP’s long-held dominance of the state. Podcaster Joe Rogan, who is based in Austin, said that Texas Republicans “passed some crazy laws banning THC products, and it’s probably cost them the election.” Goodwin said separately at a press conference this month that she is “look[ing] forward to working with all of the senators to work out those details” on cannabis legislation, saying she is “not interested in a full ban on THC.” Meanwhile, Rep. Wes Virdell (R) said that cannabis is an issue “where me and the Democrats can definitely align on.” “I think you’ll see very bipartisan bills come out of the House, and hopefully the Senate on those issues,” he said. Lawmakers in the House and Senate have already prefiled bills for the 2027 session to legalize recreational marijuana in Texas, expand medical cannabis access and enact other reforms. Hinojosa has said she wants to let Texas voters decide on marijuana legalization via a referendum, though under state law that would have to be a constitutional amendment placed on the ballot by the legislature. A strong bipartisan majority of Texans support legalizing or decriminalizing marijuana, according to recent polling. Voters in Houston this month approved a ballot initiative to make misdemeanor marijuana possession the “lowest possible enforcement priority” for local police while also banning no-knock warrants. Meanwhile, Sen.-elect James Talarico (D-TX) has said he wants to parter with President Donald Trump to federally legalize marijuana. The post Texas Should Legalize Marijuana And Use Revenue To Fund $1,500 Economic Relief Checks For Every Household In The State, Lawmaker Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  16. Two Georgia-based companies are teaming up on a new effort to deliver medical marijuana directly to patients under newly enacted state rules—and they plan to use U.S. Postal Service (USPS) certified mail for the shipments despite concerns that lawmakers have raised about the federal agency handling cannabis. On Tuesday, Botanical Sciences, a Georgia-licensed medical marijuana provider, and Edibles.com, a sister company of Edible Arrangements, announced that they will be partnering on what they said is the “nation’s first medical cannabis shipping program.” The effort comes weeks after the Georgia Access to Medical Cannabis Commission (GMCC) approved regulations that allow medical cannabis deliveries in the state, with officials specifically saying that USPS and private carriers like FedEx, UPS and DHL could participate. A spokesperson for the new partnership told Marijuana Moment on Monday that the companies will be using USPS certified mail to carry out the deliveries. “This system ensures patients can compliantly have these products shipped directly to their doors,” she said. “The platform requires us to ship the products to the address associated with their medical card and requires them to present a valid 21+ ID upon receipt. This is common for other Schedule III medications that patients commonly receive.” A spokesperson for federal agency, however, when previously contacted by Marijuana Moment, refused to clearly state whether it views delivering medical marijuana as federally legal, even under the Trump administration’s cannabis rescheduling move. They pointed to existing regulations on mailability of controlled substances without directly addressing the cannabis issue. Meanwhile, a pair of Republican U.S. Senators sent a letter last month urging USPS not to participate in medical marijuana deliveries in Georgia or other states. “It is our understanding that marijuana cannot currently be mailed at all using the USPS,” Sens. James Lankford (R-OK) and Ted Budd (R-NC) said in a letter to Postmaster General David Steiner. “However, some states are under a different impression.” “While Georgia does not have the authority to alter current USPS regulations, we are concerned that USPS will alter its regulations to allow for these shipments,” the GOP senators wrote in the letter. “We strongly oppose any effort to allow the shipment of marijuana.” The spokesperson for the new Georgia-based effort told Marijuana Moment that “it is commonplace for Schedule III drugs like ours to be shipped legally to patients.” “We followed the requirements outlined by the Georgia Medical Cannabis Commission (GMCC) and submitted our planned approach for their review and approval, which we received last week,” they said. “The goal is to ensure that products are purchased, shipped, and compliant under the Georgia medical programs. We’ve taken every step to ensure compliance at every stage of the patient’s journey.” Meanwhile, the companies say the delivery service will benefit patients, especially those who live in rural areas and don’t have convenient access to dispensaries or pharmacies that sell medical marijuana. “Georgia has created a new pathway to reach patients, and our partnership with Edibles.com allows us to translate that progress into equitable access,” Gary Long, CEO of Botanical Sciences, said in a press release. “Everything we do comes back to our commitment to serving Georgia patients and making medical cannabis more accessible to those who need it.” Thomas Winstanley, president of Edibles.com, said that “access and accountability should never be competing priorities.” “For too long, where a patient lives or their ability to travel has influenced their access to medical cannabis,” he said. “This partnership demonstrates how thoughtful regulation and technology can work together to remove those barriers without compromising the safeguards patients deserve for better quality of life.” Andrew Turnage, executive director of GMCC, the state medical cannabis regulatory agency, told Marijuana Moment on Tuesday that “it’s exciting to see licensees take advantage of the opportunity that the commission created in our recent rules amendments to allow for dispensing to occur via delivery Georgia.” The effort “addresses a legitimate need that a lot of people can clearly see,” he said. The companies said that while the new effort is Georgia-focused, it has implications that “may extend well beyond the state’s borders.” “By combining regulated medical cannabis operations with modern e-commerce infrastructure and authorized shipping, Botanical Sciences and Edibles.com are helping establish a model that other states may consider as they evaluate ways to improve patient access,” their press release says. A USPS official, when contacted by Marijuana Moment in August, declined to clearly state the agency’s position on participating in medical marijuana deliveries. Nikolaj Hagen, a senior public relations representative for USPS, pointed to general regulations on the mailability of controlled substances. Those rules state that if distribution of a controlled substance is unlawful, “then the mailing of the substance is also unlawful.” Mailing of controlled substances in domestic mail, they say, is only acceptable under three conditions—perhaps the most applicable of which allows shipping of prescription medications “when mailed by drug manufacturers or their registered agents, pharmacies, medical practitioners, or other authorized dispensers, as permitted by 21 CFR § 1307.11, or in compliance with any regulation of the FDA or other applicable law.” While state medical marijuana laws have allowed patients to access it via doctors’ recommendations, and not the formal prescription process due to federal prohibition, the cannabis rescheduling order that Attorney General Todd Blanche issued in April contains a provision that seems to deem those recommendations as prescriptions for the purposes of federal law: “Prescriptions. Notwithstanding part 1306 of this chapter or any other provision of these rules, a certification or other document (including an electronic document) that state law deems sufficient for a user to obtain marijuana or products containing marijuana for medical purposes shall be sufficient to permit dispensing of marijuana or products containing marijuana to a user so long as the certification or other document is dated as of, and signed on, the day when issued; bears the full name and address of the user; and contains the name, address, and state license number of the practitioner who signed the certification or other document and is authorized to do so under state law.” When pressed for further clarification on USPS’s position on mailing medical marijuana in light of rescheduling, Hagen simply said in August that “we have nothing additional to offer at this time.” He did not immediately reply to a new query from Marijuana Moment about the Botanical Sciences and Edibles.com effort on Tuesday. The post Georgia Companies Launch Medical Marijuana Delivery Via USPS Certified Mail As Federal Agency Refuses To Clarify Stance appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  17. A coalition of organizations representing military veterans is pushing Congress to call off a currently scheduled federal ban on hemp THC products that’s set to take effect next month and replace it with a policy that keeps them legally available with new regulations. “We share the goals that drove the current law: keeping intoxicating products away from children and ending an unregulated market,” the groups, including Veterans of Foreign Wars (VFW), wrote in a letter to House and Senate leaders on Tuesday. “A blanket ban does not achieve either. It would close compliant businesses, many of them owned or staffed by veterans, and push consumers toward unregulated sources with no testing, labeling, or age checks.” Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, the president signed new legislation containing provisions that redefined hemp to make it so only products with 0.4 milligrams of total THC per container would remain legal after November 12. Under provisions included in a separate funding bill Trump signed this September, however, the effective date of the ban for most products was pushed back to December 11 to give lawmakers more time to craft regulations for hemp derivatives. There was a carve-out, however, to allow the recriminalization on November 12 of synthetic cannabinoids “that are not capable of being naturally produced by a Cannabis sativa L. plant.” The veterans groups’ new letter says that “a federal framework can do what a ban cannot.” They are asking lawmakers to institute regulations including a minimum purchase age of 21, mandatory third-party testing and accurate labeling, child-resistant packaging with clear serving limits, oversight by a federal regulatory agency and legal protection for businesses that comply with the rules. In addition to VFW, the letter was signed by the Non Commissioned Officers Association, National American Indian Veterans, Burn Pits 360 and Grunt Style Foundation, among others. “Veterans have sacrificed for our country, and they deserve safe, responsible options for managing chronic pain, PTSD, anxiety, sleep problems, and other health conditions,” they wrote. “Many veterans, working with their healthcare providers, rely on hemp products as an alternative to opioids. If Congress fails to act, the products they depend on will suddenly become illegal, forcing them to turn to an unregulated market or go without.” “Our veterans deserve better,” the letter says. “Veterans know what it means to serve under clear rules, and we expect the same from the policies that govern products sold in our communities. We ask Congress to act before the current deadline, with a framework that protects consumers and preserves lawful commerce.” Last year, VFW entered into a partnership with Torch Drinks, a hemp THC beverage company that involved a licensing branding deal aimed at supporting veterans services and promoting cannabis drinks as a potential alcohol alternative. The agreement involved making the cannabis drinks available at VFW posts across the country in jurisdictions where they are legal. Meanwhile, a top GOP congressman is pushing to attach provisions to keep hemp products legal to larger spending legislation in the coming weeks. “The best opportunity, in my opinion, is to get this on a bill that is going to pass,” Rep. James Comer (R-KY), who chair the House Oversight and Government Reform Committee, said. “The only bill that I think that absolutely, positively has to pass is going to be another continuing resolution, which is what got us here to begin with.” Read the veterans’ hemp letter to Congress below: The post Veterans Groups Push Congress To Regulate Hemp THC Products Instead Of Banning Them appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  18. A key Republican lawmaker is floating the idea of keeping hemp THC products federally legal by attaching language to a must-pass spending bill. “The best opportunity, in my opinion, is to get this on a bill that is going to pass,” Rep. James Comer (R-KY), who chair the House Oversight and Government Reform Committee, told Spectrum News 1. “The only bill that I think that absolutely, positively has to pass is going to be another continuing resolution, which is what got us here to begin with,” he said, referring to legislation to extend funding for federal agencies past the current December 11 expiration date. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, the president signed new legislation containing provisions that redefined hemp to make it so only products with 0.4 milligrams of total THC per container would remain legal after November 12. Under provisions included in a separate funding bill Trump signed this September, however, the effective date of the ban for most products was pushed back to December 11 to give lawmakers more time to craft regulations for hemp derivatives. There was a carve-out, however, to allow the recriminalization on November 12 of synthetic cannabinoids “that are not capable of being naturally produced by a Cannabis sativa L. plant.” Industry advocates have warned that unless Congress is able to find a way to further delay or reverse the planned broader recriminalization of hemp THC products, many operators in the market will go out of business. Comer said he has “farmer friends that are planning on growing hemp next year.” “We’ve got tons of labs in the state, people that have made significant investments and it just makes me so mad because the industry is working, and it’s a huge success story,” he said. Rep. Morgan Griffith (R-VA) similarly recently floated the idea of including hemp extension and regulation language in a broader budget reconciliation bill. The Congressional Research Service noted in a recent report that the Food and Drug Administration (FDA) is now more than nine months late in fulfilling a legal mandate to publish a list of known cannabinoids and guidance on hemp product containers that was included in last year’s hemp product recriminalization legislation. A number of lawmakers from both chambers and both parties have filed or are circulating a growing number of bills to prevent the scheduled federal recriminalization of hemp THC drinks and other products. Comer, for example, is circulating legislation that would delay a planned federal ban on hemp THC products and institute some regulations—including packaging requirements, testing rules and age limits. Reps. Beth Van Duyne (R-TX) and Greg Landsman (D-OH) introduced a bill to keep hemp THC drinks legal while taxing and regulating them like alcohol. Separately, Rep. Andy Barr (R-KY), filed a lengthier proposal to prevent the federal recriminalization of hemp THC products and put in place a number of regulations for manufacturing, labeling, sales and taxation of hemp-derived products, including an age limit of 21. Griffith and Rep. Marc Veasey (D-TX) introduced a measure to allow continued sales of hemp THC products to adults over 21, with new regulations, Several Republican lawmakers recently spoke to Marijuana Moment about the kinds of rules they would like to see enacted to keep hemp THC products legal. Sens. Tim Sheehy (R-MT) and Amy Klobuchar (D-MN) are expected to soon file a hemp product regulation proposal that advocates hope to attach to broader, must-pass legislation by December 11. The post The Best Chance To Keep Hemp THC Products Legal Is By Attaching Provisions To A Larger Bill, GOP Congressman Says appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  19. WI will “definitely” legalize; Top PA senator: Marijuana not a priority; VA cannabis law tweaks; State officials org on DEA rescheduling confusion Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Marijuana Moment compiled a comprehensive look at where Senate Minority Leader Chuck Schumer (D-NY) and Sen. Chris Van Hollen (D-MD) stand on cannabis as they compete to be elected Senate majority leader for the 120th Congress. Both support federally legalizing marijuana but have placed differing emphasis on the issue—with Schumer actually filing bills to enact the policy change and Van Hollen consistently voting in favor of reform when other lawmakers have proposed legislation. Wisconsin’s incoming Senate majority leader said Democrats will “definitely” legalize marijuana during their first year in control of the legislature—and the top Republican senator indicated he’s open to discussing cannabis reform, but said he has “got to see the bill” first. Pennsylvania’s Democratic incoming Senate president pro tempore said legalizing marijuana is “not maybe necessarily one of the high priority items that we feel like we’ve been given a clear responsibility to address” in 2027—adding that cannabis is “something we will talk about in the coming months—but not necessarily right away.” The Virginia legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market voted to approve recommended changes to the state’s marijuana legalization law—including reduced fines for public consumption and enacting a ban on lawmakers having an ownership stake in the legal industry. Kentucky Gov. Andy Beshear (D) is calling on Congress to pass a marijuana banking bill—saying it would benefit his state’s medical cannabis program and is “important because it would help increase public safety, increase revenues, help our economy and improve transparency.” The Cannabis Regulators Association’s Gillian Schauer—who represents state officials across the U.S.—argues in a new Marijuana Moment op-ed that the Drug Enforcement Administration’s recent cannabis rescheduling implementation actions “have created deep uncertainty and disruption for regulators, patients and market operators” and came with “little or no advance notice to state regulators and minimal communication afterward.” “Supply chains in many states will not have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either the DEA market or the state-only market… With bifurcated and incomplete supply chains in states, some businesses will not survive in either market, patient access will be impacted, diversion and inversion will become more difficult for regulators to detect, health and safety compliance will be eroded and state revenues that support a variety of public services will decrease.” The Nebraska Medical Cannabis Commission advanced rules for the industry without making changes to provisions on testing and fees that were requested by all four of the state’s licensed cultivation businesses. / FEDERAL The National Highway Traffic Safety Administration is seeking White House Office of Management and Budget approval to conduct a survey evaluating impaired driving public education campaigns, including updating a questionnaire to “focus on not just alcohol-impaired driving, but drug-impaired, specifically cannabis, driving as well as it was not evaluated in previous surveys.” Former Pardon Attorney Ed Martin said there are “kids on marijuana all over this country that are being devastated by it.” Sen. Amy Klobuchar (D-MN) tweeted, “A federal ban on hemp products would be devastating for small businesses and jobs in Minnesota and across the country. I am fighting for a bipartisan fix to protect our state’s hemp industry.” / STATES Oklahoma Gov. Kevin Stitt (R) cited the example of a resident of his state who was deported over a marijuana charge that was expunged under state law as a federal immigration policy that doesn’t “make common sense.” Former New Jersey Gov. Chris Christie (R) discussed his opposition to legalizing marijuana but said “medical use for the appropriate conditions” is “the right thing to do.” Virginia’s Senate president pro tempore pleaded not guilty to federal corruption and marijuana-related charges. A Pennsylvania Republican representative said revenue from marijuana legalization “doesn’t account for the societal problems that that introduces as well, and the increase to human services and the rest of the fallout.” Colorado regulators issued an alert about marijuana products from a business that was burgled. California regulators are proposing to eliminate marijuana from random drug testing for certain correctional workers. Rhode Island regulators filed proposed changes to rules on marijuana business operational requirements. Maryland regulators published guidance about changes to hemp product laws. Pennsylvania’s Independent Fiscal Office noted that revenue projections for marijuana legalization are speculative. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL A Mexican senator is proposing to revive discussions about marijuana legalization. / SCIENCE & HEALTH A study found that “terpenes and cannabinoids modulate pain signalling in nociceptive neurons via distinct pathways.” A study suggested that full-spectrum cannabidiol-rich extract “pre-treatment may have chemopreventive potential against UVB-induced skin carcinogenesis.” / ADVOCACY, OPINION & ANALYSIS The Marijuana Policy Project has a new policy director and general counsel. / BUSINESS Charlotte’s Web Holdings, Inc. reported quarterly revenue of $9.4 million and a net loss of $3.5 million—saying it has generated “no revenue” so far from a federal plan to cover hemp CBD products under Medicare, and “does not anticipate meaningful” revenue related to the effort this year. Boots announced it will begin prescribing medical cannabis in the UK. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Schumer vs. Van Hollen on cannabis (Newsletter: November 17, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  20. Jennyarora

    Tokeativity Social: Harvest Moon

    Quiet nights can turn intimate quickly. Being with Female Delhi Call Girl brought a slow build of chemistry and physical closeness. Nothing felt performative. Soft moments mixed with stronger desire and the evening stayed centered on mutual comfort.
  21. moniouspea

    Eyes Wide Love: Tokeativity Back to the 90’s

    Slope offers endless rolling action with a strong focus on timing and reflexes. Players guide a fast-moving ball across floating tracks while avoiding obstacles, gaps, and dangerous edges.
  22. Your neighbor's situation is more common than we admit. Parenting young kids, schooling, and remote work at once is exhausting, and a noon glass often feels like the only break available. Her honesty that it isn't helping is the key insight. Cannabis isn't the only alternative people turn to, either. Structured breaks, peer support groups, and talking with a doctor about stress or burnout can offer real relief. Run 3 short, scheduled resets a day. Small changes can make a big difference.
  23. Explore how future love dolls modular designs could enable multiple facial expressions, allowing for more personalized and distinct character personas.
  24. Medical cannabis cultivation businesses has requested amendments on those issues. By Zach Wendling, Nebraska Examiner Proposed amendments to Nebraska’s regulations for medical cannabis establishments will proceed as-is to Attorney General Mike Hilgers (R) for legal review despite all four of the state’s licensed cultivators urging changes around testing availability and fees. The Nebraska Medical Cannabis Commission voted unanimously Monday to forward the amendments to the Nebraska AG’s Office for constitutional review. The state’s licensed cultivators sent a joint letter in October asking the commission to consider changes. Dustin Krajewski of Meadowlark Medicinals LLC, former state Sen. Kent Rogert of KRL Med LLC, Pat Thomas of MahāMotā Cultivation Co. and Robert Wagner of Midwest Cultivators Group signed the letter. If Hilgers signs off on the constitutionality of the amendments, the proposal will head to Gov. Jim Pillen (R) for approval. If he signs, the amendments would take effect five days later. Power of the commission The Legislature did not authorize the commission to assess fees until April, and the commission had already been working to finalize a prior set of regulations. The commission is refusing to grant more licenses until it can assess fees for future licenses. A MahāMotā representative said in October that the company was on track to harvest this year but saw no path to how testing facilities could legally receive, possess or test their plant. “We request an update to the current proposed regulations that provide clarification of the licensing or authorization process, who may transport samples to a laboratory, how transportation and manifest requirements apply to those transfers and whether out-of-state laboratories may be used,” the cultivators said in their letter. Under the voter-approved laws in 2024, regulatory power over “registered cannabis establishments” for the possession, manufacture, distribution, delivery and dispensing of medical cannabis is “vested exclusively” in the voter-created commission. A registered cannabis establishment is defined as a private entity licensed to possess, manufacture, distribute, deliver or dispense cannabis for medical purposes. Unless the Legislature changes that definition to include testing, the commission has no authority to grant in-state private facilities legal possession of marijuana. Proposed regulatory amendments Interim Commission Chair Lorelle Mueting had told the MahāMotā representative last month that the company had assured the commission that cannabis could be safely stored for up to two years. The commission last week clarified that it wasn’t estimating a two-year timeline before testing would be available. At the same time, the commission offered no new estimate for when testing will be available. The latest commission amendments offer a few distinct changes from current regulations, the largest of which is proposed fees for applicants—a $5,000 application fee, annual license and renewal fees based on type (between $10,000 and $28,500), a $1,500 relocation fee and a $13,000 fee for participation in the state’s seed-to-sale inventory tracking system. Dispensaries would also need to pay a $250 fee to license a new product, plus a $100 renewal fee. Currently, there are no fees under the program. Sales taxes are currently prohibited by law. The latest amendments would also merge transporter licenses with product manufacturers, so transportation would be an optional certification. Other notable changes: Removing a label that would list medical cannabis as a “Schedule I” controlled substance. In May, the federal government downgraded state-licensed medical cannabis from a Schedule I drug to a Schedule III drug. Allowing disenrollment of healthcare practitioners who voluntarily choose to participate in the program if the practitioner fails to maintain a medical license in good standing. Requiring healthcare practitioners to attest when an in-person appointment occurs before they issue a recommendation for medical cannabis. Attesting whether a provider knows whether a patient is pregnant before recommending medical cannabis. If the provider in the future learns a patient is pregnant, they must alert the commission. Current regulatory requirements The current medical cannabis regulations call for the state to: Establish a “Recommending Health Care Practitioner” directory and require patients who want to access Nebraska-licensed dispensaries to go through one of the in-state providers. Cap cultivators at no more than 1,250 flowering plants at one time. Restrict purchases of medical cannabis to 5 ounces of medical cannabis in 30 days, of which no more than 5 grams can be delta-9 tetrahydrocannabinol (THC) from the same dispensary. Delta-9 THC is the part of cannabis most associated with a “high.” Allow no more than 12 medical cannabis dispensaries statewide, arranged by judicial district. That would mean one dispensary each in Douglas County (584,526 residents), Lancaster County (322,608 residents), Sarpy/Cass counties (217,202 residents) and Buffalo/Hall counties (112,979 residents), according to 2020 census data. Prohibit the sale of smoking or vaping products and edibles of any kind. Under current state law, possession of up to 5 ounces of medical cannabis is permitted with the written recommendation of any healthcare practitioner. When asked last week whether the commission would support legislative changes ahead of the 2027 session, which begins January 6, a commission spokesperson told the Nebraska Examiner that the commission “continues to evaluate the statutory and regulatory steps necessary to fully implement Nebraska’s medical cannabis program.” The commission’s next meeting is scheduled for December 14. This story was first published by Nebraska Examiner. Photo courtesy of Chris Wallis // Side Pocket Images. The post Nebraska Officials Advance Medical Marijuana Rules Without Changes To Testing And Fees Provisions appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  25. The governor of Kentucky is pushing Congress to pass a marijuana banking bill to support his state’s rollout of a medical cannabis program. Gov. Andy Beshear (D) said at a press conference on Thursday that he joined with 15 other governors last week in sending a letter to congressional leaders in support of the Secure and Fair Enforcement Banking (SAFE) Act, which would protect banks from being punished for providing financial services to marijuana businesses. “The legislation would provide state-sanctioned cannabis businesses access to a regulated banking system,” Beshear said. “That’s important because it would help increase public safety, increase revenues, help our economy and improve transparency,” the governor said. The bill is “necessary,” he argued, because it will “keep these dollars safe and in line with federal regulations, protecting against financial crime and more.” Beshear also highlighted recent milestones in his state’s medical marijuana program, saying that “we’re making great progress to make sure that medical cannabis is available and eligible for Kentuckians in need.” “Those with sickle cell, terminal illnesses, cancer, PTSD, and others deserve alternative pain relief options,” he said. The governor noted that medical marijuana dispensaries are now open across all 11 licensing regions of the state—with 27 operational locations—and that there are now more than 30,000 registered cardholders in Kentucky’s medical cannabis program and 500 practitioners certified to issue recommendations. Beshear’s push for Congress to help ensure cannabis operators can access banking services, he said, is a “step to ensure that success continues by supporting the very businesses that make the industry possible.” The banking letter signed by the coalition of governors notes that “nearly every U.S. state has now legalized cannabis in some form,” arguing that there are public safety and other challenges caused by the “disconnect between state cannabis laws and federal law.” They wrote that states have collected billions of dollars in marijuana tax revenues, pointing out “difficulties associated with state regulatory agencies depositing those tax payments, processing licensing fees, and obtaining similar services given cannabis proceeds remain federally illegal.” The SAFE Banking Act “provides a pragmatic solution that respects state sovereignty while addressing critical public safety and governance challenges,” the letter says. Bipartisan groups of House and Senate members in June filed versions of the SAFE Banking Act in Congress. Earlier iterations of the banking legislation have been introduced in past sessions of Congress, and while versions have been approved by the House of Representatives on several occasions, the reform has never been enacted into law. The Senate Banking Committee approved a cannabis banking measure in 2023 but it was not subsequently taken up on the floor and died at the end of the 118th Congress. Last year, a bipartisan coalition of 32 state and territory attorneys general sent a letter urging Congress to pass the SAFE Banking Act, arguing that it would be “crucial to public safety and to ensuring that lawful businesses in our states have access to regulated banking services.” Photo courtesy of Mike Latimer. The post Kentucky Governor Calls On Congress To Pass Marijuana Banking Bill To Support His State’s Medical Cannabis Program appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  26. A Virginia legislative cannabis commission is recommending potential changes to the state’s newly enacted marijuana legalization policy for lawmakers to take up during the 2027 session. The legislature and Gov. Abigail Spanberger (D) earlier this year passed a measure to legalize and regulate recreational cannabis sales, though certain provisions of the law have drawn criticism from advocates—such as a move to increase fines for public consumption of marijuana. On Monday, the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market held a hearing to discuss that issue and other aspects of the legalization framework that lawmakers might consider changing when the Senate and House of Delegates reconvene in January. By way of compromise, the law that Spanberger and lawmakers agreed to makes public consumption of marijuana punishable by a civil penalty of $250 as of July 1, 2027—a significant increase from the $25 in prior law but less harsh than the class 4 criminal misdemeanor the governor sought in her proposed changes to an initial version of the legalization bill that the legislature passed earlier this year. A presentation delivered to the joint commission by the Division of Legislative Services (DLS) on Monday suggested that lawmakers consider reducing the newly proposed penalty increase, without specifying what the amount might be. The panel voted to formally recommend the issue be taken up next year, along with other proposals. It also approved a recommendation that people shouldn’t face separate charges for both public consumption of marijuana as well as possession on public school grounds for the same offense. The commission additionally voted to recommend that lawmakers take action in 2027 to clarify that local governments can adopt ordinances setting stricter requirements for the minimum distance within which marijuana businesses can be located from one another, and to set limits on how much municipalities can restrict cannabis business operating hours. Another recommendation adopted by the panel would prohibit lawmakers and members of their immediate families from holding a direct or indirect ownership interest in the state’s marijuana industry. That proposal comes as Senate President Pro Tempore Louise Lucas (D) is facing federal racketeering, marijuana distribution and money laundering conspiracy charges, with the Department of Justice alleging she used legislative influence to protect and enrich a cannabis business she co-owns. The panel also voted to recommend budget provisions to support evidence-based substance misuse programs in schools. The joint commission during the meeting additionally suggested that lawmakers make technical changes to portions of the law related to an increase of personal marijuana possession limits from one ounce to two ounces. Sen. Lashrecse Aird (D), chair of the commission, suggested that lawmakers meet again next year to consider issues such as licensing for on-site consumption licenses, micro-business cannabis event permits and the involvement of state alcohol regulators in overseeing the cannabis industry. “So we do already have a full workload heading into post session, the 2027 interim,” she said. Under the recently enacted cannabis law, recreational marijuana sales are set to begin on July 1, 2027. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — In July, the Virginia Cannabis Control Authority (CCA) launched a new online form and tip line through which people can report suspected violations of the state’s marijuana laws. Last month, CCA launched a survey asking patients about their experiences under the state’s medical cannabis program. In August, the Virginia Department of Motor Vehicles (DMV) withdrew a new ad campaign aimed at discouraging marijuana impaired driving over “concerns” that it missed the mark. The public education effort featured a 30-second spot that effectively served as an advertisement for marijuana’s relaxation-enhancing effects—telling viewers that “if you get high to relax…relax” and showing various actors engaging in activities at home such as taking a bubble bath, watching a nature documentary, gardening and eating large amounts of take-out food. Photo courtesy of Mike Latimer. The post Virginia Legislative Committee Recommends Changes To Marijuana Legalization Law For 2027 Session appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  27. “Supply chains in many states will not have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either the DEA market or the state-only market.” By Gillian L. Schauer, Cannabis Regulators Association Late last month, the Drug Enforcement Administration (DEA) took three significant actions related to federal medical marijuana rescheduling: issuing guidance to DEA applicants, issuing orders to show cause concerning DEA registration and granting the first Schedule III medical marijuana registrations. These actions have created deep uncertainty and disruption for regulators, patients and market operators. They came with little or no advance notice to state regulators and minimal communication afterward. Timely Applicant Guidance Most of the chaos in states stems from an agency-issued letter to timely applicants advising businesses that had applied for DEA registration that they can engage in Schedule III medical marijuana activities with other timely applicants and with registrants—but that they “may not lawfully engage in any schedule III medical marijuana activities with entities that did not complete an application for DEA registration between April 28, 2026 and June 26, 2026 or that have not applied for a DEA schedule III medical marijuana registration, until those entities become DEA registrants.” The letter states that if a timely applicant engages in schedule III medical marijuana activities (e.g., commerce) with someone other than a timely applicant or DEA registrant, it could be grounds for denial of their application or registration. The letter gives timely applicants until November 29 to establish compliant supply chains. This information has, virtually overnight, bifurcated most state medical marijuana marketplaces into two markets: one of DEA registrants and timely applicants, and one of state licensees who are neither DEA applicants nor registrants. Given that every state directly or indirectly outlaws interstate commerce (it is considered diversion across most states and is grounds for immediate suspension of a license) supply chains in many states will not have enough cultivators, manufacturers and dispensaries to support a viable supply chain in either the DEA market or the state-only market. Regulators and market operators across multiple states are currently trying to assess supply chain viability under this new market bifurcation. The DEA provided a list of timely applicants, but only listed de-identified DEA numbers. Regulators have been largely unable to obtain a list from DEA of the businesses in their states who are timely applicants or DEA registered and have been left to try to piece it together on their own by requesting DEA numbers from licensees. Bifurcated markets will create supply chains that are not viable, and in some cases, may create monopolies within a market. For example, one state identified that nearly three-quarters of their state-licensed dispensaries are timely applicants, leaving a small number of dispensaries in the non-DEA state-only market. Another state identified that while most state-licensed dispensaries are timely applicants, only few cultivators are, making it likely that the DEA market in that state would necessitate interstate commerce for a complete supply chain, which is illegal in that state. Another state identified that all the third-party testing labs in the state applied to be DEA registered, leaving no testing labs in the state-only market. With bifurcated and incomplete supply chains in states, some businesses will not survive in either market, patient access will be impacted, diversion and inversion will become more difficult for regulators to detect, health and safety compliance will be eroded and state revenues that support a variety of public services will decrease. Orders To Show Cause Raise Questions About DEA Registration Eligibility Across Entire States While the bifurcated DEA and non-DEA marketplace seems to be the reality for most states, DEA applicants across at least seven states or jurisdictions have received a DEA order to show cause (OSC), stating that state policies will prevent the applicant from DEA registration. DEA has flagged four main state policies in these orders: (1) dual purpose marijuana licensing approaches that permit a licensee to participate in both the medical and non-medical marketplace in the state, (2) self-certification programs wherein a patient (e.g., a veteran or patient on hospice) is able to self-certify that they have a qualifying condition for medical marijuana use in the state, (3) programs that allow dispensing without a certification or prescription and (4) synthetic cannabinoids dispensed within the medical marijuana supply chain. At this point, OSCs have typically been delivered to only a small number of applicants in each of the seven states or jurisdictions, but the orders all state that based on the identified deficiencies in state policy, DEA cannot permit any applicant operating under the state’s regime to participate in the federal registration system. Presumably, that means that all applicants in the state can expect to receive an OSC. However, applicants are receiving OSCs in an inconsistent manner, including in terms of parity within and between states, timing of OSC delivery and delivery method (e.g., via mail, in person or through a delivery service). Without communication from DEA, state regulators have been left to guess about whether all or only some applicants in the state will receive these orders. In addition, questions remain about the criteria DEA is using to issue OSCs, particularly when it comes to dual-purpose marijuana licensing programs. While several states have very similar regulations for dual-purpose licensing, only a few of those states have applicants who have received letters disqualifying their registration based on state policies. In a number of states with similar potentially disqualifying policies, applicants have received the timely applicant letter. Marketplaces are already shifting across a number of states as applicants try to come into compliance with the timely applicant letter, even though some of those states may soon be added to the OSC list and deemed ineligible. Impacts On Patients Several aspects of these DEA actions stand to impact patients directly. First, a main focus of the DEA’s OSCs was on self-certification programs, which typically exist in states to serve patients receiving hospice care, or veterans who get their care from the U.S. Department of Veterans Affairs, where clinicians are not permitted to write a recommendation or certification for medical cannabis. These programs typically represent a small proportion of state certifications and provide access to patients who cannot easily obtain a clinician’s written recommendation. Memorandums of agreement (MOAs) that timely applicants have to sign before receiving DEA registration include a section stating that dispensers agree they will not dispense marijuana to any qualifying out-of-state patient or caregiver. This means the DEA system will not allow medical reciprocity, which will make it difficult for patients to get medical marijuana when they travel to another state. Finally, the bifurcated DEA and non-DEA supply chain could have real impacts on patient access in states. For example, if a patient lives in a rural area with access to only one dispensary, and the dispensary applied for DEA registration but the manufacturer who makes the medical marijuana products the patient uses did not apply for DEA registration, then that patient could lose access to those products. Or if the supply chain is incomplete, operators in either the DEA supply chain or the state-licensed non-DEA market may go out of business altogether. The Cannabis Regulators Association (CANNRA) has continued to raise these issues to the DEA without substantive engagement. Meanwhile, regulators are trying to figure out how to continue to serve patients and regulate viable and compliant state markets without sufficient information about what DEA’s plans are now or into the future. Gillian Schauer is executive director of the Cannabis Regulators Association (CANNRA), a nonpartisan, nonprofit association of government agencies regulating cannabis, marijuana and/or hemp across more than 45 states, D.C. and three U.S. territories. The post DEA’s Approach To Marijuana Rescheduling Is Creating Deep Uncertainty For Regulators, Patients And Market Operators (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net
  1. Load more activity
×
×
  • Create New...